Literature DB >> 20551371

Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure.

Shelby D Reed1, David J Whellan, Yanhong Li, Joëlle Y Friedman, Stephen J Ellis, Ileana L Piña, Sharon J Settles, Linda Davidson-Ray, Johanna L Johnson, Lawton S Cooper, Christopher M O'Connor, Kevin A Schulman.   

Abstract

BACKGROUND: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) assigned 2331 outpatients with medically stable heart failure to exercise training or usual care. We compared medical resource use and costs incurred by these patients during follow-up. METHODS AND
RESULTS: Extensive data on medical resource use and hospital bills were collected throughout the trial for estimates of direct medical costs. Intervention costs were estimated using patient-level trial data, administrative records, and published unit costs. Mean follow-up was 2.5 years. There were 2297 hospitalizations in the exercise group and 2332 in the usual care group (P=0.92). The mean number of inpatient days was 13.6 (standard deviation [SD], 27.0) in the exercise group and 15.0 (SD, 31.4) in the usual care group (P=0.23). Other measures of resource use were similar between groups, except for trends indicating that fewer patients in the exercise group underwent high-cost inpatient procedures. Total direct medical costs per participant were an estimated $50,857 (SD, $81,488) in the exercise group and $56,177 (SD, $92,749) in the usual care group (95% confidence interval for the difference, $-12,755 to $1547; P=0.10). The direct cost of exercise training was an estimated $1006 (SD, $337). Patient time costs were an estimated $5018 (SD, $4600).
CONCLUSIONS: The cost of exercise training was relatively low for the health care system, but patients incurred significant time costs. In this economic evaluation, there was little systematic benefit in terms of overall medical resource use with this intervention. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.

Entities:  

Mesh:

Year:  2010        PMID: 20551371      PMCID: PMC3050585          DOI: 10.1161/CIRCOUTCOMES.109.907287

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  13 in total

1.  Medicare program; prospective payment system and consolidated billing for skilled nursing facilities for FY 2008. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2007-08-03

2.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors:  J N Cohn; G Tognoni
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

3.  Completing costs: patients' time.

Authors:  Louise B Russell
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

4.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2005-09-13       Impact factor: 29.690

5.  Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale.

Authors:  David J Whellan; Christopher M O'Connor; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston-Miller; Jerome L Fleg; Kevin A Schulman; Ileana L Piña
Journal:  Am Heart J       Date:  2007-02       Impact factor: 4.749

6.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

7.  Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data.

Authors:  Philip A Poole-Wilson; Bridget-Anne Kirwan; Zoltán Vokó; Sophie de Brouwer; Peter H J M Dunselman; Frederik J van Dalen; Jacobus Lubsen
Journal:  J Clin Epidemiol       Date:  2007-02-23       Impact factor: 6.437

8.  Incidence and prevalence of heart failure in elderly persons, 1994-2003.

Authors:  Lesley H Curtis; David J Whellan; Bradley G Hammill; Adrian F Hernandez; Kevin J Anstrom; Alisa M Shea; Kevin A Schulman
Journal:  Arch Intern Med       Date:  2008-02-25

9.  Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study).

Authors:  Laura R Loehr; Wayne D Rosamond; Patricia P Chang; Aaron R Folsom; Lloyd E Chambless
Journal:  Am J Cardiol       Date:  2008-02-14       Impact factor: 2.778

10.  Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

Authors:  Shelby D Reed; Joëlle Y Friedman; Eric J Velazquez; Ari Gnanasakthy; Robert M Califf; Kevin A Schulman
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

View more
  18 in total

1.  Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions.

Authors:  Shelby D Reed; Yanhong Li; Shital Kamble; Daniel Polsky; Felicia L Graham; Margaret T Bowers; Gregory P Samsa; Sara Paul; Kevin A Schulman; David J Whellan; Barbara J Riegel
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-12-06

Review 2.  Clinical utility of exercise training in chronic systolic heart failure.

Authors:  Andrew J Stewart Coats
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

3.  Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale.

Authors:  Gordon R Reeves; David J Whellan; Pamela Duncan; Christopher M O'Connor; Amy M Pastva; Joel D Eggebeen; Leigh Ann Hewston; Timothy M Morgan; Shelby D Reed; W Jack Rejeski; Robert J Mentz; Paul B Rosenberg; Dalane W Kitzman
Journal:  Am Heart J       Date:  2016-12-28       Impact factor: 4.749

4.  Economic evaluation of exercise training in patients with pulmonary hypertension.

Authors:  Nicola Ehlken; Cora Verduyn; Henning Tiede; Gerd Staehler; Gabriele Karger; Robert Nechwatal; Christian F Opitz; Hans Klose; Heinrike Wilkens; Stephan Rosenkranz; Michael Halank; Ekkehard Grünig
Journal:  Lung       Date:  2014-03-08       Impact factor: 2.584

5.  In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial).

Authors:  Shelby D Reed; Yanhong Li; Mark E Dunlap; William E Kraus; Gregory P Samsa; Kevin A Schulman; Michael R Zile; David J Whellan
Journal:  Am J Cardiol       Date:  2012-07-03       Impact factor: 2.778

6.  Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION.

Authors:  Shelby D Reed; Yanhong Li; Stephen J Ellis; John J Isitt; Sunfa Cheng; Kevin A Schulman; David J Whellan
Journal:  J Card Fail       Date:  2012-10       Impact factor: 5.712

7.  Cost-effectiveness of heart failure therapies.

Authors:  Luis E Rohde; Eduardo G Bertoldi; Livia Goldraich; Carísi A Polanczyk
Journal:  Nat Rev Cardiol       Date:  2013-04-23       Impact factor: 32.419

8.  Associations between seattle heart failure model scores and medical resource use and costs: findings from HF-ACTION.

Authors:  Yanhong Li; Wayne C Levy; Matthew P Neilson; Stephen J Ellis; David J Whellan; Kevin A Schulman; Christopher M O'Connor; Shelby D Reed
Journal:  J Card Fail       Date:  2014-06-02       Impact factor: 5.712

9.  Patient-reported selective adherence to heart failure self-care recommendations: a prospective cohort study: the Atlanta Cardiomyopathy Consortium.

Authors:  Catherine N Marti; Vasiliki V Georgiopoulou; Grigorios Giamouzis; Robert T Cole; Anjan Deka; W H W Tang; Sandra B Dunbar; Andrew L Smith; Andreas P Kalogeropoulos; Javed Butler
Journal:  Congest Heart Fail       Date:  2012-09-09

Review 10.  Exercise-based rehabilitation for heart failure.

Authors:  Rod S Taylor; Viral A Sagar; Ed J Davies; Simon Briscoe; Andrew J S Coats; Hayes Dalal; Fiona Lough; Karen Rees; Sally Singh
Journal:  Cochrane Database Syst Rev       Date:  2014-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.